Abrocitinib在健康人、银屑病及特应性皮炎患者中的群体药代动力学
本研究基于11项临床试验、995名健康人或银屑病/特应性皮炎患者的数据,建立Abrocitinib群体药代动力学模型。模型采用二室模型、平行零级和一级吸收、时间依赖生物利用度及时间与剂量依赖清除。协变量分析显示亚洲种族(体重校正后Cmax和AUC分别升高1.43和1.48倍)和青少年年龄是暴露变异的关键因素,但临床意义不大;与利福平合用暴露降低,与氟康唑/氟伏沙明合用、炎症性皮肤病及肝损伤暴露升高,但均无需据此调整剂量。
要点
- 亚洲人种体重校正后Cmax和AUC分别升高1.43和1.48倍,但无需调整剂量。
- 利福平合用降低Abrocitinib暴露,氟康唑/氟伏沙明合用及肝损伤升高暴露。
- 青少年与成人按总体重校正后暴露分布相似,无需按年龄调整剂量。
核心结论
- Abrocitinib群体药代动力学模型可预测药物相互作用或内在患者因素下的稳态暴露。
- 亚洲种族和青少年年龄是暴露变异的关键协变量,但临床意义不大。
- 基于年龄、种族、性别、体重、肝功能及药物相互作用等因素,无需调整Abrocitinib剂量。
研究设计与样本
- 基于11项临床试验(7项I期、2项II期、2项III期)的995名个体,共6206个Abrocitinib浓度测量值。
- 研究对象包括健康人、银屑病患者和特应性皮炎患者。
- 采用非线性混合效应模型建模,并用最终模型模拟剂量比例性和稳态蓄积。
主要发现
- 最终模型为二室模型,含平行零级和一级吸收、时间依赖生物利用度及时间与剂量依赖清除。
- 与利福平合用导致Abrocitinib暴露降低。
- 与氟康唑和氟伏沙明合用、亚洲/其他种族、炎症性皮肤病(银屑病/特应性皮炎)及肝损伤导致暴露升高。
- 体重校正后,亚洲受试者Cmax和AUC分别升高1.43倍和1.48倍。
- 按总体重校正后,青少年与成人暴露分布相似。
临床怎么用
- 临床无需根据年龄、种族、性别、体重、肝功能或药物相互作用调整Abrocitinib剂量。
- 合用利福平、氟康唑或氟伏沙明时,可参考模型预测暴露变化,但无需常规剂量调整。
局限性
- 原文未明确报告模型的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Abrocitinib is a Janus kinase 1 inhibitor in development for the treatment of atopic dermatitis (AD). This work characterized orally administered abrocitinib population pharmacokinetics in healthy individuals, patients with psoriasis, and patients with AD and the effects of covariates on abrocitinib exposure. METHODS: Abrocitinib concentration measurements (n = 6206) from 995 individuals from 11 clinical trials (seven phase I, two phase II, and two phase III) were analyzed, and a non-linear mixed-effects model was developed. Simulations of abrocitinib dose proportionality and steady-state accumulation of maximal plasma drug concentration (Cmax) and area under the curve (AUC) were conducted using the final model. RESULTS: A two-compartment model with parallel zero- and first-order absorption, time-dependent bioavailability, and time- and dose-dependent clearance best described abrocitinib pharmacokinetics. Abrocitinib coadministration with rifampin resulted in lower exposure, whereas Asian/other race coadministration with fluconazole and fluvoxamine, inflammatory skin conditions (psoriasis/AD), and hepatic impairment resulted in higher exposure. After differences in body weight are accounted for, Asian participants demonstrated a 1.43- and 1.48-fold increase in Cmax and AUC, respectively. The overall distribution of exposures (Cmax and AUC) was similar in adolescents and adults after accounting for differences in total body weight. CONCLUSIONS: A population pharmacokinetics model was developed for abrocitinib that can be used to predict abrocitinib steady-state exposure in the presence of drug-drug interaction effects or intrinsic patient factors. Key covariates in the study population accounting for variability in abrocitinib exposures are Asian race and adolescent age, although these factors are not clinically meaningful. CLINICAL TRIAL NUMBERS: NCT01835197, NCT02163161, NCT02201524, NCT02780167, NCT03349060, NCT03575871, NCT03634345, NCT03637790, NCT03626415, NCT03386279, NCT03937258. Abrocitinib is a drug approved in the UK and Japan for the treatment of atopic dermatitis. A population pharmacokinetic model for abrocitinib was developed based on data from 11 clinical trials that included 995 healthy individuals or patients with atopic dermatitis or psoriasis. Simulations of different patient factors, such as age, race, sex, body weight, liver function, and drug–drug interactions, were tested to examine differences in abrocitinib drug levels achieved in the body. The results of these simulations indicate that although there are some differences in abrocitinib exposure, no dose adjustments of abrocitinib are necessary based on these factors.
引用
- Wojciechowski J, Malhotra BK, Wang X, et al. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis. Clin Pharmacokinet. 2022. PMID: 35061234. doi:10.1007/s40262-021-01104-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。